Renal homotransplantation in man: followup of 189 cases by Starzl, TE et al.
ONCOLOGY 1970 
Being the Proceedings of the 
Tenth International Cancer Congress 
Volulne II 
Experimental Cancer 
Therapy 
Edited and Prepared for Publication 
under the Di1-ection of: 
R. LEE CLARK, M.D., M.Sc. (SURG.), D.Sc. (HON.) 
President, The University of Texas M. D. Anderson Hospital 
and Tumor Institute at Houston 
and Chairman, National Organizing Committee of the 
Tenth Intemational Cancer Congress 
RUSSELL W. CUMLEY, PH.D. 
Editor and Head. Department of Publications, 
The University of Texas M. D. Anderson Hospital and Tumor Institute at HoUston 
JOAN E. McCAY, M.A. 
Alanaging Editor and Supervisor of Pull/ieations, Depal-/menl of Publications, 
The University of Texas AT. D. A Ilciersol1 Hospital and Tumor Institute at Houston 
MURRAY M. COPELAND, M.D., D.Sc. (HON.) 
Professor of SW'gel:V (Oncology), The Univel-sit)' of Texas M. D. 
Andenon Hospital and Tumor Institute at Houston 
Ilnd Sen-Ptal,,)' Geneml. Tenth International Clltlrer COrll!;>"e.,", 
WITH THE COOPERATION OF THE 
OFFICIALS OF THE TENTH Il"TERNATIONAL CANCER CONGRESS 
YEAR BOOK MEDICAL PUBLISHERS INC. 
~R EAST WACKER DRIVE CHICAGO 
RENAL HOMOTRANSPL.-\i\:TATION IN MAN / 411 
Renal Homotransplantation in Man: 
Follow-up of 189 Cases 
THOMAS E. STARZL, M.D., 
HIROSHI TAKAGI, M.D., 
SAMUEL H. GRAY, M.D., AND 
GERARD MARTINEAU. M.D. 
Univenity of ColOJ'ado Medical Center and Denver Veterans 
Administration Hospital, Denver, Colorado, USA 
AT THE Sixth National Cancer Conference held in 1968, we discussed 
organ transplantation as a possible adjuvant measure in the treatment 
for cancer as, for example, by using liver replacement to permit the ex-
tirpation of a hepatoma that could not be resected by partial hepatec-
tomy. Three lines of evidence were presented2 that this concept migh t be 
at least partly self-defeating. This evidence indicated that the necessary 
antirejection therapy confidently could be expected to erode those im-
mune defenses which might slow the natural growth of a malignancy in 
the event of incomplete removal. 
The objective of the present report is quite different. It is simply to 
say something about the practical value of renal homotransplantation 
in patients with kidney failure due to nonneoplastic disease. The opin-
ions will be based on our experience with 189 recipients who were treat-
ed long enough ago so that relatively long potential follow-ups are avail-
able in each case. Attention will be drawn again to the fact that chronic 
survivors after renal homotransplantation are unusually prone to the de-
velopment of a variety of de novo malignant conditions. The following 
account has been abstracted from a much more complete description of 
I'hese same cases.1 
Survival 
INTRAFAMILTAL TRANSPLANTATION 
A posItIve judgment about the practical value of renal homotrans-
plantation was not difficult with related cases, since even at the begin-
ning there was a substantial benefit if homografts were obtained from 
family members. In Figure 11-6 is shown the graphic fate of 131 con-
secutive patients who received kidneys [rom siblings, parents, or more 
distantly related donors such as aunts, uncles, and cousins. The follow-
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FIGURE 11-5.-Life survival curves in the three series of intrafamilial renal homo-
transplantations described in the text. In Series III, the patients have been studied 
for at least 27 months. The follow-ups in Series II and I are for a minimum of four 
and six and one-fourth years, respectively. At the end of each survival curve a 
numerator and denominator are given. The denominator tells the number of living 
patients, and the numerator denotes the number of original homografts that are 
still functioning, 
up in Series I is now six and one-fourth to seven and two-thirds years, in 
Series II from four to five and one-half years, and in Series III from 
two and one-fourth to four years. 
The 71 patients of Series I and II were treated with azathioprine and 
prednisone. About two thirds of these patients lived for at least two 
years and subsequent deaths have been relatively uncommon, so that 57% 
of the combined Series I and II survive to date after four to seven and 
two-thirds years. The patients of Series III had heterologous antilympho-
cyte globulin (ALG) in addition to azathioprine and prednisone. In the 
60 cases of Series III, the survival at one year was 92%, at two years 88%, 
and currently, after two to [our years, it is 85%. 
The over-all results were not remarkably influenced by the type of 
donor-recipient consanguinity. The present survival is about 70% in all 
related recipients treated in Denver from two and one-fourth to seven 
and two-thirds years ago, without regard to the kinship of the donor, 
RENAL el~glqoAkpmiAkqAqflly INl\L\r\ 
TABLE I l-S.-RESULTS OF fkqoAtKy~gfifAi 
TRANSPLANTATION 
Sibling 
Parental 
Others 
4-1/66 
40/55 
7flO 
E~ to 7 \/:! years) 
(67%) 
(73%) 
(70%) 
/ 4Pi 
whether these were siblings, parents, or more distant relatives Cfable 
ll-5) . 
UNRELATED TKANSPLANTATlON 
With the 58 transplantations between nonrelatives (both volunteers 
or cadaveric donors) , the results were inferior to those with blood rela-
tives. In Figure 11-7, the Series I, II, and III conform to the same inter-
vals already defined above in the related cases, except that in Series III 
FI(;uRE 11-7.-Life survival curves in the three series of nomelated renal homo-
transplantations described in the text. The minimum follow-ups in Series I, II. and 
[II are six and one-fourth. four and two-thirds. and one years. The significance 
uf the numerators and denominators at t.he end of each cnrve is the same as in 
Figure I 1-6 . 
z 
o 
t-
u 
« 
a: 
... 
. 
. 
. 9 \\ 
,8 yy~----­
\ \ 
.7 \ \,\\ 
,6 \ \,\\ 
ill (11/111 
\ '-. 
': \ \-----\------------.. 
SERIES I - 18 VOLUNTEERS 
SERIES II (TYPED)- 17 VOLUNTEERS 
AND 6 CADAVERS 
SERIES ill (ALGI - 17 CADAVERS 
,3 
- \ ---- ._-\._--------------\. __ . 
L --"\ \!l __ (4/61 
.2 ~-y 
\. ________ 1_ -(liZ) 
ll-----S-----1~O----1~U----O~4----Pa~--~~~--~4~O--~4~U--~R~4----S~l~--~~~~TO 
TIME IN MONTHS 
414 / STARzLetal. 
the minimum follow-up was one rather than two years. In the 1962 and 
1963 era (Series I), only 33% (six of 18) of the recipients survived for 
a year. From 1964 to 1966, this figure rose to 52% (12 of 23). In Series 
III the one-year survival in the nonrelated cases was 82%, or 14 of 17 pa-
tients. Subsequent to one year in all three series the losses continued at 
a rather steady rate, far more frequently than in the related cases (com-
pare Figures 11-6 and 11-7) , so [hat only 19 (or 33%) of these 58 recipi-
ents remain alive today. Even in the ALG-treated patients of Series III, 
the final survival in nonrelated cases has drifted off so that it is now 65%: 
INFLUENCE OF ANTIGEN COMPATIBILITY 
In most of the foregoing cases, Dr. Paul Terasaki of Los Angeles 
analyzed the antig'ens in the peripheral lymphocytes of both donors and 
recipients by his cytotoxicity test. The antigen compatibility as expressed 
by the well-known A-D scoring designation was then correlated with the 
clinical outcome. 
In the sibling cases, the well-matched (A and B) kidneys tended to 
have an advantage over the combined Cs and Ds in terms of survival 
and function. With genetic analysis, it was then established that these 
well-matched organs tended to be from donors who had identity with 
the recipients of both haplotypes of the HL-A chromosome; 88% of all 
compatible organs transplanted in Denver between siblings are stilI 
functioning, as opposed to 74% in the less favored cases (Table 11-6). 
The advantage of double haplotype identity in the sibling recipients 
was easily identified in a series of biopsies taken two years after opera-
tion, and graded on a scale of 0-4 as to the presence or absence of a 
number of abnormalities, including those shown in Table 11-7. The 
HL-A identical sibling kidneys had fewer and less severe glomerular and 
vascular lesions, as well as less pronounced cell invasion and immuno-
globulin deposition. 
With other donor-recipient relationships (even parent to offspring 
transplantations) there was no significant correlation between the A-D 
matching grades and the outcome. The same was true with the com-
pletely unrelated cases. The series of B, C, and D matched unrelated kid-
neys are shown in Table U-8; the one-year survival was the same under 
TABLE 1I-6.--SIBLlNG TRANSPLANTATION-HAPLOTYPE "S. OUTCOMf. 
Double Haplotype 
Identity (p;:: 0.7) 
.\11 Ot.hers 
o 
16 
3:; 
6 
15(94%) 
3.1i (100%) 
SIIM.VIV.,\L E;yrlkqff~F 
12 2,1 (:111 nOli' (:!,j·Hfi Inns.) 
1.5 (94%) 
113 (94%) 
15 E94«~IF 
31 (89";,) 
14 (RR%) 
!?fl(H%) 
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TABLE 11-7.-DouBLE HAI'LOTYl'E s~K PATHOLUG\ 
No. OF CASES GLOMERULAR MONONUCLEAR VASCULAR IGM 
TWtI Haplotype 
Id"lIlical (I' ~ 0.7) 13 0.60 0.39 0.39 O.!i'i 
OLher Siblings 28 1.61 1.21 1.50 1.12 
P <0.013 <0.003 <0.003 <0.003 <0.01 
TABLE 11-S.-U!\RELATED DfoAkpmiAkqAqll~ MATCH VS. Oun:o.\a: 
SURVI\·.\!. (MONTHS) 
MATCH 0 6 12 Current (12·60 mos.) 
B 8 5 (62.5%) :; (62.:;%) 3 (37.5%) 
c 1'1 12 (71 %) 12 (il %) il (47%) 
D 9 8 (89%) 6 (67%) 4 (44%) 
Totals 34 25 (74%) 23 (68%) 15 (44%) 
all three circumstances. The same applied to subsequent follow-ups of 
one to five years. 
It is important to comment about these negative findings in the 
parent to offspring and nonrelated cases, if only to avoid the unwar-
ranted conclusion that tissue matching is an obsolete concept. A 
discussion of several possible explanations for the lack of correlations 
has been published elsewhere,l but one point is worth re-emphasizing. 
That is that the A-D grades represent only a statement as it were in 
shorthand about the data available in a given case. It is probable that the 
alphabetical designations do not optimally express the information that 
can be extracted from the raw typing data. Rapaport and Dausset have 
recently published evidence to this effect, and in fact Rapaport has per-
sonally demonstrated to us that this may be true in our own cases. It 
seems clear that the first step in improving the situation with tissue 
matching will be re-examination of the original data so carefully col-
lected by Terasaki and by others, with a view to its reinterpretation. 
H.omograft Glomerulonephritis 
Another controversial question about renal transplantation concerns 
the frequency with which glomerulonephritis affects kidneys transplant-
ed to recipients whose native organs were destroyed by such an autoim-
mune process or even to recipients with renal failure from a nonimmu-
nologic etiology. In 105 of the homografts of our series examined with 
light microscopy, electron microscopy, and immunofluorescence a year 
or more after operation, many varieties of glomerulonephritis were 
seen: (1) with antiglomerular base membrane antibody (Masugi ne-
phritis) , (2) with antigen-antibody complexes deposited in the subepi-
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TABLE 11-9~dilMborilkbmeoiqfp 
(105 COMPLETE STUDlFS) 
No Glomerulonephritis 
Possi ble Glomerulonephritis 
Definite Glomerulonephritis 
• 23 examples of "transmission" 
32 (3U.5%) 
23 (21.9%) 
.'i0 (47.6%) * 
thelial location, (3) with complexes in the subendothelial location, or 
(4) with complexes in both locations. The findings were related to those 
with light microscopic examination, and a designation was made of 
membranous, proliferative, and lobular glomerulonephritis. 
Of the 105 biopsied grafts, only 30% were completely free of glo-
merulonephritis as has just been defined. Half the kidneys had obvious 
glomerulonephritis and another 20% had this diagnosis as a possibility 
(Table 11-9). Thus, a high incidence of glomerulonephritis in these kidneys 
was a matter of fact. The etiology of the lesions was another question. 
Evidence will be given in another publication1 that the majority of these 
glomerulonephritides developed as a form of antibody-mediated indo-
lent rejection. For example, there was no other way to explain why 
glomerulonephritis developed in homografts transplanted to patients 
v,hose original disease was oxalosis, cystinosis, polycystic disease, and 
pyelonephritis. Conversely, there was evidence in many cases that pre-
existing host glomerulonephritis was "transmitted" to the transplants. In 
23 such instances, the glomerulonephritis in the grafts was a faithful or 
nearly faithful anatomic recapitulation of the same disease that had de· 
strayed the native kidneys (Table 11·9) . 
Human Thymectomy 
From four to five and one-half years ago, a human thymectomy study 
was carried out. During that time, 24 patients had their thymus glands 
excised prior to transplantation, whereas a similar number of control re-
cipients did not. The thymectomy patients have not enjoyed any kind of 
advantage in terms of lowered mortality or improved renal function. 1 
However, somewhat surprisingly, the homografts in the thymectomy se· 
ries have had less severe glomerular, arterial, infiltrative, and other le-
sions (Table 11·10). Thus, the question of thymectomy as an adjuvant 
suppressive measure in humans must be kept open at this time. 
Non-Thymectomy 
Thymectomy 
TABLE 11-11I._'!'YPE OF HISTOLO(;TC \BNORMALlTY 
(;.IO:\1.l:Rt'T."\R \lnERf:\! INFILTRATF 
f:K!~F 1.41 1A1 1K~T 
1!!4) .R!l . ;~I Kfi~ (P < KllK~F 
Ir.r. 
.93 
.14 (P < .O:!) 
These figures rcpr~:Diel1t (he me:lIl ."'("(Ire in e;lch grollp with ~rKulillg lIn ,I 0 to -t .'icaJe according 
to severity. 
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TABLE II-II .-i\lALlGNANT TmloRs 
(189 RECIPIENTS) 
Epithelial 7 
Cured 7 
l\J esench Yl1lal 3 
Cured 1 
Total lO" 
• Incidence (5.3%) 
ALG 3/10 
The Risk of Malignancy 
The harmful effects of chronic immunosuppression are so well known 
that such things as fatal infections have not even been mentioned in 
this report. An increased incidence of de novo malignant disease is an-
other less recognized penalty for chronic immunosuppression. Of the se-
ries of 189 patients presented today, seven have developed carcinomas 
and three have developed lymphomas for an uncorrected total incidence 
of 5.3% (Table ll-ll). Moreover, two of the patients have died from 
widespread tumor metastases (both reticulum cell sarcomas) . The inci-
dence of malignant disease has been the same before and after the in-
troduction of ALG. 
The development of malignant tumors in renal transplant recipients 
has not been confined to the University of Colorado. In 16 other cen-
ters, 27 de novo malignant tumors (14 carcinomas and 13 mesenchymal 
neoplasms) have been reported1 to an informal registry established in 
Denver for such cases by Dr. Israel Penn. As in our recipients, the prog-
nostic implications of the mesenchymal tumors were grave, and only one 
of these patients remains alive. In contrast, nine of 14 patients with car-
cinomas were successfully treated. 
Summary 
Since most of this paper has been devoted t~ an exposition of the dan-
gers and deficiencies of renal transplantation, an appropriate balance 
might be given by summarizing on an optimistic note. Of the 189 pa-
tients treated by kidney transplantation from more than one to seven 
and one-half years ago, llO are still alive. A procedure which can result 
in this kind of prolongation of life can have deficiencies and still have 
real practical value. 
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Introduction 
THE SUCCESSFUL USE of allogeneic bone marrow grafts in the treatment 
of accidentally irradiated persons16 led us to believe that total body ir-
radiation would be a good method of suppressing immunologic reactions 
before leukemic patients were treated with allogeneic bone marrow 
grafts. Since 1959, we have given 24 patients with acute leukemia allo-
geneic marrow grafts after total body irradiation. In 17 cases the grafts 
were successful, but in only five could the acute secondary disease be 
controlled.17• 18, 22, 28 Secondary disease can be prevented or cured in 
animals by giving methotrexate20, 31, ~9I 40 or cyclophosphamide,21,31 by 
incubating the donor cells at 37 C before trans£usionI~P or by giving an-
tilymphocyte serum. fI In man, however, none of these methods has been 
really efficient.28 , 41 The two components in secondary disease are a prolif-
eration of lymphocytes, which infiltrate many tissues, especially the skin 
